Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -9,036 | -15,116 | -8,498 | 45,981 |
| Gain on sale of investments | NaN | 71 | 0 | 3 |
| Stock-based compensation expense | 1,447 | 1,412 | 1,739 | 3,477 |
| Depreciation expense | 27 | 66 | 86 | 173 |
| (accretion) amortization on investments | 162 | 149 | 292 | 838 |
| Impairment of right-of-use assets and property and equipment | NaN | 7,348 | NaN | NaN |
| Noncash rent expense | 546 | 714 | 791 | 1,549 |
| (gain) loss on sale of equipment | 0 | 3 | 1 | 23 |
| Prepaid expenses and other current assets | 921 | 251 | -475 | 573 |
| Other non-current assets | -44 | -44 | -44 | -88 |
| Accounts payable | 2,390 | -396 | 204 | -3,236 |
| Accrued expenses and other current liabilities | -3,587 | 582 | -1,464 | -532 |
| Non-current operating lease liabilities | -980 | -967 | -934 | -1,812 |
| Net cash provided by (used in) operating activities | -10,232 | -6,787 | -7,850 | 44,251 |
| Proceeds from sale of equipment | 0 | 3 | 1 | 23 |
| Proceeds from sales and maturities of investments | 19,500 | 33,011 | 23,500 | 62,583 |
| Purchases of investments | 0 | 35,903 | 14,911 | 113,212 |
| Net cash provided by (used in) investing activities | 19,500 | -2,889 | 8,590 | -50,606 |
| Proceeds from exercise of common stock options and espp, net of restricted stock surrendered for taxes | -185 | -196 | 134 | -84 |
| Proceeds from issuance of common stock, net of issuance costs | NaN | 0 | 0 | 0 |
| Net cash provided by financing activities | -185 | -196 | 134 | -84 |
| Net (decrease) increase in cash and cash equivalents | 9,083 | -9,872 | 874 | -6,439 |
| Cash, cash equivalents and restricted cash, beginning of period | 21,819 | 31,691 | 37,256 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 30,902 | 21,819 | 31,691 | NaN |